|
1
|
Villano JL, Koshy M, Shaikh H, Dolecek TA
and McCarthy BJ: Age, gender and racial differences in incidence
and survival in primary CNS lymphoma. Br J Cancer. 105:1414–1418.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mead GM, Bleehen NM, Gregor A, Bullimore
J, Shirley D, Rampling RP, Trevor J, Glaser MG, Lantos P, Ironside
JW, et al: A medical research council randomized trial in patients
with primary cerebral non-Hodgkin lymphoma: Cerebral radiotherapy
with and without cyclophosphamide, doxorubicin, vincristine and
prednisone chemotherapy. Cancer. 89:1359–1370. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Korfel A and Uschlegel: Diagnosis and
treatment of primary CNS lymphoma. Nat Rev Neurol. 9:317–327. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nelson DF, Martz KL, Bonner H, Nelson JS,
Newall J, Kerman HD, Thomson JW and Murray KJ: Non-Hodgkin's
lymphoma of the brain: Can high dose, large volume radiation
therapy improve survival? Report on a prospective trial by the
radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat
Oncol Biol Phys. 23:9–17. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laperriere NJ, Cerezo L, Milosevic MF,
Wong CS, Patterson B and Panzarella T: Primary lymphoma of brain:
Results of management of a modern cohort with radiation therapy.
Radiother Oncol. 43:247–252. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
DeAngelis LM, Yahalom J, Thaler HT and
Kher U: Combined modality therapy for primary CNS lymphoma. J Clin
Oncol. 10:635–643. 1992.PubMed/NCBI
|
|
7
|
Abrey LE, DeAngelis LM and Yahalom J:
Long-term survival in primary CNS lymphoma. J Clin Oncol.
16:859–863. 1998.PubMed/NCBI
|
|
8
|
Morris PG and Abrey LE: Therapeutic
challenges in primary CNS lymphoma. Lancet Neurol. 8:581–592. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Omuro AM, Ben-Porat LS, Panageas KS, Kim
AK, Correa DD, Yahalom J, Deangelis LM and Abrey LE: Delayed
neurotoxicity in primary central nervous system lymphoma. Arch
Neurol. 62:1595–1600. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Batchelor T, Carson K, O'Neill A, Grossman
SA, Alavi J, New P, Hochberg F and Priet R: Treatment of primary
CNS lymphoma with methotrexate and deferred radiotherapy: A report
of NABTT 96–07. J Clin Oncol. 21:1044–9. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Herrlinger U, Schabet M, Brugger W,
Kortmann RD, Küker W, Deckert M, Engel C, Schmeck-Lindenau HJ,
Mergenthaler HG, Krauseneck P, et al: German cancer society
neuro-oncology working group NOA-03 multicenter trial of
single-agent high-dose methotrexate for primary central nervous
system lymphoma. Ann Neurol. 51:247–252. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thiel E, Korfel A, Martus P, Kanz L,
Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T,
Hundsberger T, et al: High-dose methotrexate with or without whole
brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase
3, randomised, non-inferiority trial. Lancet Oncol. 11:1036–1047.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferreri AJ, Reni M, Foppoli M, Martelli M,
Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G,
Ilariucci F, et al: High-dose cytarabine plus high-dose
methotrexate versus high-dose methotrexate alone in patients with
primary CNS lymphoma: A randomised phase 2 trial. Lancet.
374:1512–1520. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chamberlain MC and Johnston SK: High-dose
methotrexate and rituximab with deferred radiotherapy for newly
diagnosed primary B-cell CNS lymphoma. Neuro Oncol. 12:736–744.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Birnbaum T, Stadler EA, von Baumgarten L
and Straube A: Rituximab significantly improves complete response
rate in patients with primary CNS lymphoma. J Neurooncol.
109:285–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shah GD, Yahalom J, Correa DD, Lai RK,
Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM and Abrey LE:
Combined immunochemotherapy with reduced whole-brain radiotherapy
for newly diagnosed primary CNS lymphoma. J Clin Oncol.
25:4730–4735. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wieduwilt MJ, Valles F, Issa S, Behler CM,
Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, et
al: Immunochemotherapy with intensive consolidation for primary CNS
lymphoma: A pilot study and prognostic assessment by
diffusion-weighted MRI. Clin Cancer Res. 18:1146–1155. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fritsch K, Kasenda B, Hader C, Nikkhah G,
Prinz M, Haug V, Haug S, Ihorst G, Finke J and Illerhaus G:
Immunochemotherapy with rituximab, methotrexate, procarbazine and
lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann
Oncol. 22:2080–2085. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Filley CM and Kleinschmidt-DeMasters BK:
Toxic leukoencephalopathy. N Engl J Med. 345:425–432. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gavrilovic IT, Hormigo A, Yahalom J,
DeAngelis LM and Abrey LE: Long-term follow-up of high-dose
methotrexate-based therapy with and without whole brain irradiation
for newly diagnosed primary CNS lymphoma. J Clin Oncol.
24:4570–4574. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cang S, Mukhi N, Wang K and Liu D: Novel
CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol.
5:642012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maloney DG, Grillo-López AJ, Bodkin DJ,
White CA, Liles TM, Royston I, Varns C, Rosenberg J and Levy R:
IDEC-C2B8: Results of a phase I multiple-dose trial in patients
with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 15:3266–3274.
1997.PubMed/NCBI
|
|
23
|
Ruhstaller TW, Amsler U and Cerny T:
Rituximab: Active treatment of central nervous system involvement
by non-Hodgkin's lymphoma? Ann Oncol. 11:374–375. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Holdhoff M, Ambady P, Abdelaziz A, Sarai
G, Bonekamp D, Blakeley J, Grossman SA and Ye X: High-dose
methotrexate with or without rituximab in newly diagnosed primary
CNS lymphoma. Neurology. 83:235–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Illerhaus G, Marks R, Müller F, Ihorst G,
Feuerhake F, Deckert M, Ostertag C and Finke J: High-dose
methotrexate combined with procarbazine and CCNU for primary CNS
lymphoma in the elderly: Results of a prospective pilot and phase
II study. Ann Oncol. 20:319–325. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gerstner ER and Batchelo TT: Primary
central nervous system lymphoma. Arch Neurol. 67:291–297. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Batchelor TT, Grossman SA, Mikkelsen T, Ye
X, Desideri S and Lesser GJ: Rituximab monotherapy for patients
with recurrent primary CNS lymphoma. Neurology. 76:929–930. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wong ET, Tishler R, Barron L and Wu JK:
Immunochemotherapy with rituximab and temozolomide for central
nervous system lymphomas. Cancer. 101:139–145. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Enting RH, Demopoulos A, DeAngelis LM and
Abrey LE: Salvage therapy for primary CNS lymphoma with a
combination of rituximab and temozolomide. Neurology. 63:901–903.
2004. View Article : Google Scholar : PubMed/NCBI
|
